NovoCure Ltd — Director's Dealing 2019

Jan 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-01-11

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-11	Ordinary Shares	M	8751	$14.37	Acquired	25838	Direct
2019-01-11	Ordinary Shares	S	8751	$42.004	Disposed	17087	Direct
2019-01-11	Ordinary Shares	M	17500	$11.46	Acquired	34587	Direct
2019-01-11	Ordinary Shares	S	17500	$42.004	Disposed	17087	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-11	Options to Buy Ordinary Shares	$14.37	M	8751	Disposed	2025-02-23	Ordinary Shares (8751)	Direct
2019-01-11	Options to Buy Ordinary Shares	$11.46	M	17500	Disposed	2026-02-24	Ordinary Shares (17500)	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.

F2: On January 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 8,751 shares in multiple trades at prices ranging from $42.00 to $42.03. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On January 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 17,500 shares in multiple trades at prices ranging from $42.00 to $42.03. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: Options exercised were fully vested as of the date hereof.